Clinical Value Of Ultrasound Guided Percutaneous Radiofrequency Ablation Combined With Portal Vein Chemoembolization In The Liver Cancer Treatment

Objective To explore the efficacy and safety of ultrasound guided radiofrequency ablation combined with portal vein chemoembolization in the treatment of liver cancer.Methods The clinical data of 56 patients with liver cancer, which were all confirmed to be liver cancer by pathological or clinical manifestations,24 patients treated by radiofrequency ablation combined with portal vein chemoembolization(RFA+PVCE group) and 32 patients treated only by radiofrequency ablation (RFA group),were analyzed retrospectively. The liver function, tumor activity index and the two groups of postoperative complications, complete ablation rate, local recurrence rate and tumor free survival rate were compared between the two groups, The results were statistically analyzed.Results The two groups of patients with a total of 56 cases were all successfully completed the treatment. ① On the 3th day after operation, the liver function indexes of two groups were significantly higher than that before operation(P< 0.05), and there was no significant difference between the two groups(P> 0.05), and the liver function recovered to the preoperative level after 7 days.②2 weeks after operation, the levels of AFP、CA-199 and GGT-II in human serum samples were significantly different between RFA+PVCE group and RFA group (t=7.284、6.824、7.892, P<0.05) ③ There were no serious complications in both groups, but slight complications were observed in 4 of 24 patients (16.7%) in RFA+PVCE group and in 4 of 32 patients (12.5%) in RFA group, the difference between the two groups has no significance(x2=0.698,P=0.502).④ One month after operation, all patients were examined by CT enhance scan and contrast-enhanced ultrasound(CEUS), RFA+PVCE group complete ablation rate was 87.5%(21/24), RFA group complete ablation rate was 75% (24/32), two groups of complete ablation rate difference was statistically significant (x2=3.183, p=0.045).⑤RFA+PVCE group of postoperative local recurrence rate was 12.5%(3/24), RFA group of postoperative local recurrence was 31.25%(10/32), and the difference between the two groups was statistically significant (p=0.043); The 1,2 years disease-free survival rates of RFA+PVCE group were 75%,62.5%, RFA group of 1,2 years without tumor were 50%, 40.6%, but there was no significant difference between the two groups (p=0.112).Conclusion The portal vein chemoembolization can enhance the effect of radiofrequency ablation in the treatment of liver cancer, improve the complete ablation rate, reduce the recurrence rate of patients, disease-free survival can be improved. Radiofrequency ablation combined with portal vein chemoembolization in the treatment of liver cancer is safe and reliable, the postoperative effect of liver function was limited, and the incidence rate of complications was not increased.